Boxer Capital’s Verrica Pharmaceuticals VRCA Stock Holding History

Boxer Capital’s Portfolio VRCA Stock Details VRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-16,696	Closed	-$649K	–	71
2023 Q3	$649K	Buy	+16,696	New	+$848K	0.03%	66

Other funds holding VRCA

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

MML Investors Services Springfield, Massachusetts $49B AUM 25.55% 1-Year Est. Return

Boxer Capital's VRCA Position: Q4 2023 in Review

Boxer Capital sold out of Verrica Pharmaceuticals (VRCA) in Q4 2023, closing a stake of 16,696 shares — an estimated $649K sold.

Boxer Capital first reported a position in VRCA in Q3 2023 and held it in 1 quarter. The position peaked at $649K in Q3 2023. 64 funds tracked by Wall St. Rank hold VRCA as of Q4 2023.

Boxer Capital reported no remaining Verrica Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Boxer Capital sold 16,696 Verrica Pharmaceuticals shares in Q4 2023, an estimated $649K.
Boxer Capital first reported a position in Verrica Pharmaceuticals in Q3 2023 and held it in 1 quarter.
Boxer Capital's Verrica Pharmaceuticals position peaked at $649K in Q3 2023.
64 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q4 2023.

Based on Boxer Capital's 13F filing for Q4 2023, filed 14 Feb 2024.